Find Paid Clinical Trials in Japan

Paid Clinical Trials and Focus Groups by Location

All Locations ... Japan

A Phase 1 Study of IMC-11F8 in Patients With Advanced Solid Tumors

Condition: Advanced Solid Tumors
Interventions: Biological: IMC-11F8; Biological: IMC-11F8; Biological: IMC-11F8
Sponsors: ImClone LLC; Parexel
Recruiting - verified March 2010
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Placebo; Drug: Glimepiride
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Asthma Exacerbation Study

Condition: Asthma
Interventions: Drug: Fluticasone Furoate/GW642444; Drug: Fluticasone furoate
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan

Conditions: Angina; Chronic Coronary Occlusion; Stent Thrombosis; Vascular Disease; Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis
Intervention: Device: XIENCE V / PROMUS stent placement
Sponsor: Abbott Vascular
Recruiting - verified March 2010
ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis

Conditions: Renal Impairment; Hemodialysis; Anemia
Intervention: Drug: ASP1517
Sponsor: Astellas Pharma Inc
Recruiting - verified March 2010
Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)

Condition: Bladder Cancer
Interventions: Drug: Bacille Calmette-Guerin; Drug: uracil-tegafur
Sponsor: Urological Oncology Council of Northern Tokyo
Recruiting - verified March 2010
Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Condition: Idiopathic Restless Legs Syndrome
Interventions: Drug: SPM 962; Drug: SPM 962; Drug: Placebo of SPM 962
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Recruiting - verified March 2010
PROMUS Element Japan Small Vessel Trial

Conditions: Atherosclerosis; Coronary Artery Disease
Intervention: Device: PROMUS Element™
Sponsor: Boston Scientific Corporation
Recruiting - verified March 2010
Study With Two Different Doses of Desmopressin Melt Tablet With Nocturnal Enuresis

Condition: Nocturnal Enuresis
Interventions: Drug: Desmopressin; Drug: Placebo
Sponsor: Ferring Pharmaceuticals
Recruiting - verified February 2010
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Condition: Leukaemia, Lymphocytic, Chronic
Intervention: Drug: ofatumumab 100 mg, 1000 mg / vial
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Drug Use Investigation of Kaletra

Condition: Human Immunodeficiency Virus
Intervention:
Sponsor: Abbott
Active, not recruiting - verified February 2010
Special Investigation of Kaletra in Pregnant Women

Condition: Human Immunodeficiency Virus
Intervention:
Sponsor: Abbott
Recruiting - verified February 2010
Drug Use Investigation for Humira -All Patient Investigation for Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Intervention:
Sponsor: Abbott
Recruiting - verified February 2010
A Trial of Telmisartan Prevention of Cardiovascular Disease

Condition: Hypertension
Interventions: Drug: Non-ARB (standard therapy); Drug: ARB (Telmisartan)
Sponsor: Kumamoto University
Recruiting - verified June 2009
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: ZD9393 (Zoladex); Drug: ZD9393 (Zoladex)
Sponsor: AstraZeneca
Not yet recruiting - verified February 2010
Endothelial Function After Drug-Eluting Stent (DES)

Conditions: Coronary Artery Disease; Atherosclerosis
Interventions: Device: zotarolimus-eluting stent (ENDEAVOR®); Device: sirolimus-eluting stents (CYPHER SELECT® PLUS); Device: everolimus-eluting stents (PROMUS®)
Sponsor: Hyogo College of Medicine
Not yet recruiting - verified February 2010
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN1250; Drug: insulin detemir (Levemir®); Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Condition: Chronic Plaque-type Psoriasis
Interventions: Drug: AIN457; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified February 2010
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MP-513; Drug: MP-513; Drug: Placebo of MP-513
Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting - verified February 2010
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors

Condition: Solid Tumors
Interventions: Drug: MK2206 every other day; Drug: MK2206 once weekly
Sponsor: Merck
Recruiting - verified March 2010
Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin

Condition: Prevention
Interventions: Drug: D961H; Drug: Placebo
Sponsor: AstraZeneca
Recruiting - verified February 2010
Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan

Condition: Coronary Artery Disease
Interventions: Drug: Clopidogrel; Drug: Clopidogrel; Drug: Clopidogrel; Drug: Clopidogrel
Sponsor: Kyoto University, Graduate School of Medicine
Recruiting - verified March 2010
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Intervention: Biological: HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides
Sponsors: Shiga University; Human Genome Center, Institute of Medical Science, University of Tokyo
Not yet recruiting - verified February 2010
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Intervention: Biological: HLA-A*2402-restricted CDCA1 and KIF20A peptides
Sponsors: Shiga University; Human Genome Center, Institute of Medical Science, University of Tokyo
Not yet recruiting - verified February 2010
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Intervention: Biological: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides
Sponsors: Shiga University; Human Genome Center, Institute of Medical Science, University of Tokyo
Not yet recruiting - verified February 2010

Find Paid Clinical Trials in Japan - Clinical Trials

Find Paid Clinical Trials in Japan

Paid Clinical Trials and Focus Groups by Location

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials